Ofatumumab Clinical Trials

4 actively recruiting trials across 1 location

▼ -1 trial since June 2026

Also known as: Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

M.D. Anderson Cancer Center2
Third Affiliated Hospital, Sun Yat-Sen University1
The First People's Hospital of Changzhou1

Indications

Cancer3
B Lymphoblastic Lymphoma1
B Acute Lymphoblastic Leukemia1
Multiple Sclerosis1
Refractory Lymphoblastic Lymphoma1

Other2 trials

Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels

Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

Phase 3

Houston, Texas2 trials

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 2

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.